As the new year approaches, Mr. Song Lai, Chairman of Linuo Pharmaceutical Packaging, released his 2026 New Year message, sharing reflections on the company’s 2025 performance and outlining a strategic roadmap focused on high-quality, high-certainty growth.
Strategic Milestones in a Pivotal Year
2025 marked a milestone year for Linuo Pharmaceutical Packaging, coinciding with the conclusion of China’s 14th Five-Year Plan and the strategic positioning phase of the 15th Five-Year Plan. During the year, the company achieved systematic breakthroughs across globalization, industrial integration, and organic growth.
Linuo Pharmaceutical Packaging strengthened its global footprint through strategic cooperation with Brazil’s SANTISA and U.S.-based Xseer, while acquiring equity in Suzhou Chuangyang New Materials to enhance integrated packaging capabilities. These initiatives accelerated market entry into high-growth regions such as South America and the Middle East and reinforced supply chain autonomy.
Capacity Expansion and High-End Product Focus
To support long-term competitiveness, the company continued to direct capital toward high-end pharmaceutical packaging, including RTU (Ready-to-Use) solutions and Prefilled Syringes (PFS). In 2025, the successful commissioning of the second furnace for molded middle borosilicate glass bottles marked the formal release of core production capacity, laying a solid foundation for sustained growth.
At the same time, Linuo Pharmaceutical Packaging established Shandong Linuo Intelligent Robotics Co., Ltd. as a wholly owned subsidiary, extending its strategy beyond core manufacturing and forming a new growth curve based on intelligent automation capabilities.
Brand Globalization and Value Creation
The company’s specialty glass business also completed a major upgrade, entering global markets under the independent international brand BOROHOUSE. This transition signaled a shift from pure capacity output toward an integrated global operating model combining brand, technology, channels, and e-commerce, expanding value creation potential and earnings certainty.
Chairman Song emphasized that these strategic initiatives are being continuously translated into sustainable growth momentum and long-term shareholder value, supported by prudent governance and disciplined execution.
Looking Ahead to 2026
Against the backdrop of structural changes in capital markets and a shift from scale-driven growth to quality-driven evaluation, Linuo Pharmaceutical Packaging has proactively aligned its strategy around high quality, high efficiency, and high value creation.
In 2026, the company will further strengthen its industrial foundations, optimize governance structures, and formally advance initiatives in investment and financing, technological innovation, data management, AI application, and digital business models, supporting long-term, resilient development.
Chairman Song reaffirmed the company’s commitment to product-focused innovation, long-term value creation, and stakeholder-oriented growth, expressing confidence in navigating economic cycles and delivering sustainable returns to investors.
Learn more about Linuo Pharmaceutical Packaging’s strategy and business developments at:
: https://www.linuo-pharma.com
For broader context on China’s Five-Year Plan framework and industrial policy direction, visit the official portal of the National Development and Reform Commission:
: https://www.ndrc.gov.cn
